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Pentoxifylline Diminishes the Oxidative Damage to Renal
Tissue Induced by Streptozotocin in the Rat
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Department of Pharmacology and Physiology, Faculty of Medicine, Universidad Aut´ onoma de San Luis
Potos´ ı, San Luis Potosi, M´ exico
Oxidative damage has been suggested to be a contribut-
ing factor in the development to diabetic nephropathy
(DN). Recently, there has been evidence that pentoxifylline
(PTX)hasfreeradical-scavengingproperties;thus,itsanti-
inﬂammatoryandrenoprotectiveeffectsmayberelatedtoa
reduction in reactive oxygen species production. It is likely
that the pharmacological effects of PTX include an antiox-
idant mechanism as shown in in vitro assays. The aim of
this study was to evaluate whether the reported renopro-
tective effects of PTX could be the result of its antioxidant
actionsinstreptozotocin(STZ)-inducedDNinrats.Thead-
ministration of PTX over a period of 8 weeks, in addition
to displaying renoprotective effects, caused a signiﬁcant re-
ductioninlipoperoxidelevels(LPOS)inthediabetickidney
(P<0.05), compared to untreated rats. These levels were
comparable to those in the healthy kidney of experimen-
tal animals (P > 0.05). All untreated STZ rats exhibited
an increase in LPOS as opposed to healthy controls (H)
(P<0.001). The total antioxidant activity (TAA) in plasma
was increased signiﬁcantly already after 2 days of STZ
(P<0.05). When we examined the progression of TAA in
STZ rats, there was a signiﬁcant decrease over 8 weeks
(P<0.05). PTX treatment caused an increase in TAA
when compared to untreated STZ rats (P<0.05).
Renal hypertrophy was less evident in PTX-treated
STZ than in untreated STZ rats, evaluated by kid-
ney weight/body weight ratio. These results indicate
that PTX decreases the oxidative damage induced by these
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experimental procedures and may increase antioxidant
defense mechanisms in STZ-induced diabetes in rats.
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INTRODUCTION
Diabeticnephropathy(DN)isoneofthemaincausesofend-
stagerenaldisease.Themetaboliceventsresponsibleforitsde-
velopment are not yet completely understood. Poor glycemic
control undoubtedly plays a signiﬁcant part, as shown by both
clinical[1]andpathologicalstudies[2].Amongallmechanisms
known to trigger and worsen DN, the production of reactive
oxygen species (ROS) may play a crucial role. Possible medi-
ators of untoward effects of hyperglycemia include advanced
glycation end products (AGEs), known to accumulate in tis-
sues as a function of time and glucose concentration [3]. These
harmful products promotes ROS formation in cells and tissues
[4, 5]. AGEs and ROS-induced cellular damage promote dys-
functions that interfere with the genetic expression of peptides
and cytokines. Hence perturbed redox balance may determine
cell proliferation and vascular function during the development
ofdiabeticcomplications[6–8].Thus,theseresponsesmayplay
a crucial role in the genesis of DN.
Evidencesuggeststhatintheearlystagesofdiabetes,appro-
priate interventions aimed at improving glycemic control, low-
ering hypertension and decreasing microalbuminuria [1, 9] can
signiﬁcantly delay the progression of renal disease. Drugs used
in the treatment of other diseases have shown pharmacologi-
cal properties that preserve or even ameliorate renal function.
Angiotensin-converting enzyme inhibitors (ACEI) have been
usedwithrelativelygoodsuccessintreatingDN[10].However,
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pharmacological alternatives must be explored, since some pa-
tients with DN cannot be treated with ACEI due to intoler-
ance or allergic reactions to these drugs. In this context, PTX, a
methylxanthinederivativewithrheologicalproperties,hasbeen
proposedasaprotectorofrenalfunctioninDN.Severalstudies
havereportedthatPTXreducesurinaryproteinexcretioninpa-
tientswithtype2diabetesprogressingtowardrenaldysfunction
and advanced renal failure [11–13], as well as in experimental
nephritic syndrome [14]. Methylxanthines and their derivates
are nonspeciﬁc phosphodiesterases inhibitors (PDEI) most fre-
quently used for the modulation of macrophage functions [15].
They are recognized as powerful suppressors of inﬂammatory
cell function. However, the precise mechanism of their action
is still poorly understood.
Recently, PTX has gained considerable interest as a ROS
scavenger. Several in vitro studies have conﬁrmed the poten-
tial antioxidant effects of this drug [16–19]. Although PTX has
been established as a renoprotective drug, its contribution in
protecting the kidney from high glucose toxicity by damping
ROS production has not been investigated in DN where oxida-
tive stress is involved. Thus, the purpose of this study was to
investigate the effect of PTX administration on lipoperoxides
(LPOS = malondialdehyde and 4-hydroxy-2 nonenal, as an in-
dex of lipid peroxidation in the kidney) and total antioxidant
activity (TAA) and to correlate the results with renoprotective
effect in STZ-induced diabetes in rats. We also examined renal
and biochemical parameters at 2 days after STZ and after the
4th and 8th weeks of PTX treatment.
MATERIALS AND METHODS
Animals
Studies were performed using male Sprague-Dawley rats
weighing 230 to 290 g. The guidelines of our institution for the
care and use of laboratory animals was observed. The rats were
fed with standard diet and were given water ad libitum.
Diabetes Induction
Diabetes was induced by a single intraperitoneal (i.p) injec-
tion of streptozotocin (65 mg/kg body weight [b.w.]) freshly
dissolved in sterile saline. Healthy control rats (H) received
equivalent amounts of saline i.p. Blood samples were drawn
2 days later and the diabetes was conﬁrmed by measuring the
level of blood glucose, using a reﬂectance meter (One Touch
Basic, LifeScan J & J, Milpitas, CA, USA). Only rats with
bloodglucoselevels≥250mg/dLwereincluded.Threegroups
(n = 9 each) were established by a randomized method as
follows: control group (H), diabetic group without treatment
(STZ),andpentoxifylline-treateddiabeticgroup(STZ+PTX).
The latter group received daily doses of PTX at 80 mg/kg b.w.
administered i.p. whereas the H and STZ group received only
placebo. The animals used were housed in metabolic cages,
maintained at 24◦C and constant humidity (60%) with a 12 h
light:dark cycle. Urine volume and water and food intake per
24 hrs were monitored daily during the whole experiment. Fur-
thermore at day 2, and then every week body weight of the
animals was monitored.
Animals were sacriﬁced after 4- and 8-weeks of diabetes.
Rats were weighed prior to sacriﬁce, and 24-h urine samples
werecollectedtodeterminealbuminexcretionrate(UalbV).Ad-
ditionally, blood samples were drawn to quantify TAA, and the
kidneys were removed, weighed and analyzed for LPOS (mal-
ondialdehyde and 4-hydroxy-2-nonenal) as an index of lipid
peroxidation.
Tissue Preparation
Rats were anesthetized with ether. Blood samples were ob-
tained by cardiac puncture and collected in EDTA tubes in
order to analyze the following biochemical parameters; creati-
nine,glucose,glycosylatedhemoglobinfraction%HbA1c,total
cholesterol, and triglycerides. Kidneys were removed, cleaned
of perirenal tissue, blotted dry and weighed. Subsequently, kid-
neys were processed for LPOS determination. Minced renal
tissue was homogenized in 20 mM phosphate buffer (pH 7.4)
containing butylated hydroxytoluene (BTH) at a ﬁnal concen-
tration of 5 mM at 4◦C for 30 sec (2 × 15 sec with a 15-
sec cooling interval) using a polytron homogenizer (Teckman
Model TR-10, Cincinnati, OH, USA). The homogenate was
centrifuged at 3000 × g for 10 min at 4◦C (Sorvall RC-5B, Du
pont Instruments, Wilmington, DE, USA ). The resultant su-
pernatant was used to measure LPOS by the colorimetric assay
BIOXYTECH,LPO586(OxisInternational,Inc.,Portland,OR
USA).
Biochemical Assays
HbA1C was measured using the tina-quant assay [20] in
an automatic analyzer. Total plasma concentrations of choles-
terol,triglyceridesandcreatinineweremeasuredenzymatically
in a Hitachi 911 clinical chemistry analyzer (Manufacturer
Roche/BMC, Palo Alto, CA USA). TAA was measured by a
colorimetric technique as described by Miller et al. [21] using
a commercial kit (Randox Laboratories LTD, UK). Twenty-
four-hour urine samples were obtained from animals kept in
metabolic cages with access only to drinking water. Creati-
nine was measured as well as albumin concentration deter-
mined by radioimmunoassays (Euro/Diagnostic Products Cor-
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Preparation of Pancreas Sections and Histochemical Analyses
The rats were anesthetized using pentobarbital sodium.
A midline abdominal incision was made and pancreas was
removed from the rat and ﬁxed overnight in a solution of
10% Formaldehyde. Fixed tissues were processed routinely for
parafﬁn embedding and ∼5 µm sections were prepared and
mounted on slides. Staining was performance on this slides
with Hematoxylin and Eosin.
Statistical Data Analysis
Results were expressed as means ± standard error of the
mean (SEM). The results obtained for the quantitative fac-
tors studied (glucose, %HbA1C, total plasma cholesterol and
triglycerides, UalbV and 24-h creatinine clearance: CCr) were
compared among the groups by applying one-way analysis of
variance test. Signiﬁcance was set at P < 0.05 in all cases.
RESULTS
All STZ rats exhibited biochemical signs of diabetes. They
presented hyperglycemia, with blood concentrations higher
than 250 mg/dL 2 days after STZ administration (Table 1),
thus conﬁrming the diabetic state of the animals. Additionally,
hypercholesterolemia and hypertriglyceridemia were observed
at 2 days of diabetes and remained elevated throughout the
experiment.
Levels of blood glucose and plasma total cholesterol and
triglycerides did not differ between untreated rats and PTX-
treated STZ rats at the end of treatment. Mean blood glucose
TABLE 1
Effects of streptozotocin-induced diabetes and pentoxifylline on metabolic parameters
measured at 2 days and at 4 and 8 weeks
Glucose Cholesterol Triglycerides
Animal group (mg%) %HbA1C (mg%) (mg%)
H( n= 9)
2 days 95.2 ± 9.00 4.95 ± 0.63 46.90 ± 3.23 63 ± 0.13
4 weeks 94.8 ± 10.70 5.37 ± 0.24 44.50 ± 3.16 84 ± 12.55
8 weeks 102.6 ± 15.30 4.85 ± 0.07 45.50 ± 5.20 64 ± 7.93
STZ (n = 9)
2 days 314.5 ± 14.60∗ 4.86 ± 0.99 98.85 ± 8.89∗ 283 ± 45.02∗
4 weeks 358.3 ± 48.90∗ 8.37 ± 0.27∗ 87.91 ± 12.63∗ 250 ± 69.41∗
8 weeks 282.4 ± 21.70∗ 9.09 ± 0.40∗,b 88.78 ± 14.57∗ 334 ± 178.46∗
STZ + PTX (n = 9)
2 days 273.2 ± 14.20∗ 4.62 ± 1.40 72.18 ± 7.41∗ 367 ± 83.81∗
4 weeks 289.5 ± 23.70∗ 8.32 ± 0.05∗ 76.82 ± 8.67∗ 152 ± 42.69∗
8 weeks 296.7 ± 12.50∗ 7.21 ± 0.40∗,a 71.86 ± 18.77∗ 244 ± 75.33∗
Data are means ± SEM, ∗P < 0.05 signiﬁcantly different from the healthy rats.
aSigniﬁcantly different from STZ + PTX group at 2 days, P < 0.05.
bSigniﬁcantly different from STZ + PTX group at 8 weeks, P < 0.05.
n = number of animals.
levels, as measured by HbA1C, were consistently higher in
STZ rats at the fourth week, reﬂecting and verifying the hyper-
glycemic condition during the experiment. A progressive de-
creaseinHbA1CwasseeninPTX-treatedSTZrats,reachingsta-
tistical signiﬁcance after 8 weeks of treatment (7.21±0.40 vs.
9.09±0.40%untreatedSTZrats, P < 0.05).Conversely,there
wasaprogressive increase in untreated STZ rats (9.09 ± 0.40
vs. 4.86 ± 0.99%, P < 0.05).
Table 2 shows changes in renal functional parameters. At
the beginning of the experiment, urinary volume (UV) was sig-
niﬁcantly increased in STZ rats in comparison to healthy rats
(83.25 ± 3.62 vs. 21.80 ± 1.31 mL/24 h, P < 0.0001), a func-
tional hallmark of the diabetic state. Signiﬁcantly increased
urine volumes persisted in 4- and 8- week untreated STZ and
PTX-treated STZ rats.
As expected, uncontrolled diabetes resulted in glomerular
hyperﬁltration (1.09 ± 0.23 mL/min/100 g b.w., P < 0.05 at
4 weeks), remaining high at the end of the experiment, this
high rate was partially reversed by PTX therapy (to 0.77 ±
0.06 mL/min/100 g b.w., P > 0.05).
TherewasasigniﬁcantincreaseinUalbVat2daysofdiabetes
(0.40 ± 0.07 vs. 0.0020 ±0.0001 mg/day before STZ, P <
0.0001), a clear progression toward proteinuria in the untreated
STZ rats (0.70 ± 0.24 mg/day by week 8) was observed. On
the other hand, the PTX-treated STZ rats showed a prevention
at increased UalbV (0.27 ± 0.15 mg/day, P < 0.05) at the end
of the experiment.
LPOS levels were signiﬁcantly elevated in all STZ rats at 2
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TABLE 2
Renal function in STZ and STZ + PTX rats
UV CCr UalbV
Animal group (mL/24 h) (mL/min/100 g b.w.) (mg/day)
H( n= 9)
2 days 21.80 ± 1.31 0.85 ± 0.10 0.0020 ± 0.0001
4 weeks 20.39 ± 2.18 0.94 ± 0.12 0.0023 ± 0.0003
8 weeks 21.49 ± 3.26 1.08 ± 0.12 0.0021 ± 0.0003
STZ (n = 9)
2 days 83.25 ± 3.62∗ 0.71 ± 0.08 0.40 ± 0.07∗∗
4 weeks 120.54 ± 14.05∗ 1.09 ± 0.23a 0.49 ± 0.15∗∗
8 weeks 103.20 ± 11.57∗ 0.85 ± 0.09 0.70 ± 0.24∗∗
STZ + PTX (n = 9)
2 days 79.92 ± 5.58∗ 0.98 ± 0.15 0.40 ± 0.15∗∗
4 weeks 100.67 ± 9.18∗ 0.77 ± 0.06 0.46 ± 0.72∗∗
8 weeks 98.91 ± 7.28∗ 0.82 ± 0.08 0.27 ± 0.15∗∗,b
Data are means ± SEM, ∗P < 0.05 signiﬁcantly different from H group at 2 days and 4 and 8
weeks.
∗∗P < 0.0001 signiﬁcantly different from H group at 2 days and 4 and 8 weeks.
aSigniﬁcantly different from STZ rats at 2 days; P < 0.05.
bSigniﬁcantly different from STZ rats at 8 weeks; P < 0.05.
UV = urinary volume, CCr = creatinine clearance, UalbV = albumin excretion rate,
n = number of animals.
as shown in Table 3 (4.5 ± 0.7 and 5.3 ± 0.5 vs. 2.0 ± 0.3 µM
LPO/g, both P < 0.05). LPOS levels increased during the
8 weeks in untreated STZ-rats (4.5 ± 0.7 vs. 9.9 ± 1.7 µM
LPO/g, P < 0.05). On the other hand PTX-treatment was as-
TABLE 3
Effect of STZ-induced diabetes and PTX on LPOS
and TAA measured at t = 0( 2days), 4 weeks and 8 weeks
Animal group µM LPOS/g tissue TAA mmol/L
H( n= 9)
2 days 2.0 ± 0.3 1.0 ± 0.3
4 weeks 2.3 ± 0.6 1.2 ± 0.3
8 weeks 2.1 ± 0.4 0.9 ± 0.2
STZ (n = 9)
2 days 4.5 ± 0.7∗ 2.4 ± 0.5∗
4 weeks 6.4 ± 0.8∗ 3.4 ± 0.9∗
8 weeks 9.9 ± 1.7∗∗,a 1.6 ± 0.2b
STZ + PTX (n = 9)
2 days 5.3 ± 0.5∗ 2.9 ± 0.5∗
4 weeks 4.5 ± 0.4∗ 1.8 ± 0.4∗
8 weeks 3.5 ± 1.1∗ 3.8 ± 0.2c
Data are means ± SEM,
∗P < 0.05 signiﬁcantly different from H rats at 2 days.
∗∗P < 0.001 signiﬁcantly different from H rats at 8 weeks.
aP < 0.05 signiﬁcantly different from STZ + PTX rats at 8 weeks.
bP < 0.05 signiﬁcantly different from STZ rats at 2 days.
cP < 0.05 signiﬁcantly different from STZ rats at 8 weeks.
LPOS = lipoperoxides, TAA = total antioxidant activity.
sociate with a decline in LPOS ( 5.3 ± 0.5 vs. 3.5 ± 1.1 µM
LPO/g, P < 0.05).
LPOS levels in the PTX-treated STZ rats at 8 weeks did not
differ from those of the healthy group (3.5 ± 1.1 vs. 2.1 ±
0.41 µM LPO/g, P > 0.5). TAA in plasma at the beginning of
the experiment (2 days) was found to be signiﬁcantly increased
in STZ rats compared to healthy rats (2.40 ± 0.5 vs. 1.0 ±
0.26 mmol/L, P < 0.05). When we examined the progression
of TAA in STZ rats, this activity decreased signiﬁcantly over
the 8 week period (2.4 ± 0.5 vs. 1.6 ± 0.2 mmol/L, P < 0.05).
PTX-treatedSTZratsattheendoftheexperimenthadincreased
TAAl evels when compared to untreated STZ rats (3.8 ± 0.2
vs. 1.6 ± 0.2 mmol/L, P < 0.05).
During the experiment body weight diminished in rats with
untreatedSTZdiabetescomparedtohealthyrats(266.6±14.12
vs. 355.7 ± 8.77 g, P < 0.05; Table 4). The food intake was
equally increased in STZ and PTX-treated STZ-rats at 4 and 8
weeks.
Kidneyweight/bodyweightratio,anindexofrenalhypertro-
phy(Table5),wasincreasedinbothSTZandPTX-treatedSTZ-
rats, although this tended to be less in PTX-treated STZ rats.
The diabetogenic action of STZ was quantitatively evalu-
ated by counting the pancreatic β cells number with a light
microscope, 2 days after its administration, also at 8 weeks of
the experiment, ﬁnding a severe reduction in this parameter, in
comparison to healthy rat (2 ± 2 vs. 10 ± 2 β cells number/10
ﬁelds, P < 0.05, at 8 weeks). An increase of these cells, wasPENTOXIFYLLINE AS ANTIOXIDANT IN VIVO 249
TABLE 4
Effect of STZ-induced diabetes and PTX on body weight
and food intake/24h measured at t = 0( 2days), 4 weeks
and 8 weeks
Body weight Food intake
Animal group (g) (g/24 h)
H( n= 9)
2 days 260.00 ± 3.86 23.80 ± 1.70
4 weeks 333.22 ± 14.30a 26.01 ± 2.02
8 weeks 355.70 ± 8.77a 27.32 ± 1.33
STZ (n = 9)
2 days 284.29 ± 10.84 22.32 ± 1.33
4 weeks 261.22 ± 11.52∗ 33.66 ± 1.64∗
8 weeks 266.60 ± 14.12∗∗ 32.72 ± 3.03∗∗
STZ + PTX (n = 9)
2 days 278.36 ± 7.18 21.79 ± 1.50
4 weeks 242.43 ± 18.55∗ 35.50 ± 1.22∗
8 weeks 277.91 ± 23.21∗∗ 35.29 ± 1.75∗∗
Data are means ± SEM,
∗P < 0.05 signiﬁcantly different from H rats at 4 weeks.
∗∗P < 0.05 signiﬁcantly different from H rats at 8 weeks.
aP < 0.000001 signiﬁcantly different from H rats at 2 days.
observed in the PTX-treated STZ-rats at the end of the experi-
ment. (2 ± 2 vs. 6 ± 1 β cells number/10 ﬁelds, P < 0.05).
DISCUSSION
Our results provide evidence that the administration of PTX
to STZ rats over a period of 8 weeks, in addition to displaying
renoprotective effects, causes a highly signiﬁcant reduction in
LPOSlevelsinthediabetickidneytolevelscomparabletothose
in the kidney of non-diabetic animals. The antioxidant system
as reﬂected by TAA was increased after 8 weeks of treatment,
suggestingthatthePTXcouldscavengeROSandpotentiatethe
activity of the antioxidant system in this model.
It has been suggested that antioxidant treatment preserves
pancreaticβ cellfunctionthroughreductionofoxidativestress,
TABLE 5
Kidney weight/body weight ratio and pancreatic
β cells number
Animal group Kidney weight/body Pancreatic β cells
n = 9 weight ratio g/100 g number/10 ﬁelds
H 0.397 ± 0.008 10 ± 2
STZ 0.576 ± 0.028∗ 2 ± 2∗
STZ + PTX 0.512 ± 0.020∗ 6 ± 1∗,a
Data are means ± SEM,
∗P < 0.05 signiﬁcantly different from H rats.
aP < 0.05 signiﬁcantly different from STZ rats.
as well as by diminishing β cells apoptosis without inﬂuencing
the rate of β cell proliferation [22]. This observation is com-
patible with our experimental observation of β cells number
at the end of the PTX treatment. This parameter was found
to be increased, therefore it seems reasonable that the preser-
vation β cells through improved glycemic control by PTX. In
this study we evaluated HbA1c as an index of metabolic con-
trol. This HbA1c was decreased at the end of the study in the
treated rats. These ﬁndings are in concordance with previous
evidencereportingthatPTXcouldinhibitglycation[23]reduc-
ing glucose auto- oxidation, diminishing the oxidative damage
to pancreatic β cell, with improvement in insulin secretion.
Reactive oxygen species (ROS) have been invoked as im-
portant signal mediators for cell surface receptors, acting as
signaling agents in the regulation of several cellular processes,
including those during the cell cycle entry [24–26]. Likewise
Chen et al. [27] have reported that PTX suppresses the acti-
vation and proliferation of mesangial cells, thereby prevent-
ing the development of proteinuria in experimental mesangial
proliferative glomerulonephritis, also observed in other exper-
imental models of nephropathy in which renal function was
evaluated [14]. Thus, the ﬁnal antiproteinuric effect observed
in the present study and in others may be explained in terms of
the free radical scavenging properties of PTX.
Among nonspeciﬁc PDEI, the protective effect of PTX in
autoimmune disease is well documented [28, 29]. While the
beneﬁcial effects of PTX in autoimmunity are usually linked
toinhibitionofTNF-α productionandT-cellproliferation[30].
Recentdatahaveimpliedtheinvolvementofinduciblenitricox-
idesynthase(iNOS)andnitricoxide(NO)asamechanisminthe
protectionexertedbyPTXinautoimmunediabetes[31].More-
over, if we take into account its antioxidant properties, these
mayleadtomodulationsofiNOSresultinginadown-regulation
of NO production, with cytoprotective effects. Therefore, an
antioxidant mechanism may be responsible for its beneﬁcial
actions.
Our data indicate that renal hypertrophy was prevented by
PTX treatment, thereby normalizing renal function. Changes
in renal function in untreated STZ rats were distinguished by
glomerular hyperﬁltration and microalbuminuria, and estab-
lished renal hypertrophy.
Becausediabetesisconsideredachronicillnessanditscom-
plications may occur earlier than expected, it was necessary to
determine whether STZ-induced changes that occurred during
the time of the experiment could be prevented by PTX treat-
ment after 4 to 8 weeks. In this study, we observed that 8 weeks
of PTX treatment in experimental diabetes reduced LPOS and
increased TAA. The effect was not evident until after 4 weeks
treatment. The decrease in TAA in untreated STZ rats after
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mechanisms through glycation of scavenging enzymes. Like-
wise, gene expression of antioxidant enzymes in pancreatic
islets has been shown to be decreased by Lenzen et al. [32].
The usefulness of antioxidants in the treatment of diabetes
has been reported in several studies, mainly in preventing
complications and maintaining plasma glucose levels. Admin-
istration of antioxidants has been shown to improve insulin
efﬁciency and glycemic equilibrium. Interestingly, these drugs
potentiate the antihypertensive action of insulin in rats [33].
Some antidiabetic agents may have antioxidant properties
independent of their role in glucose control. It also has been
shown that thiazolidinediones and sulfonylureas [34] possess
these properties. Therefore, in addition to their effectiveness in
glycemic control, these drugs have an antioxidant activity that
has not been evaluated in DN.
Insummary,thepresentresultssuggestthatmultiplemecha-
nisms are likely to mediate cellular injury in response to oxida-
tive stress generated during the development of complications
of diabetes and that they are potentially subject to modulation
byantioxidanttherapy.Thus,thisstudysupportsthehypothesis
that the spectrum of pharmacological effects exerted by PTX
may be attributed to its ability to scavenge ROS. Therefore,
treatment with PTX may offer metabolic beneﬁts resulting in
a decrease in the progression of renal disease in experimental
diabetes.
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